1-8 of 8
Sophie Postel-Vinay
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Translational Aspects of Epithelioid Sarcoma: Current Consensus

Thomas G.P. Grünewald, Sophie Postel-Vinay, Robert T. Nakayama, Noah E. Berlow, Andrea Bolzicco, Vincenzo Cerullo, Josephine K. Dermawan, Anna Maria Frezza, Antoine Italiano, Jia Xiang Jin, Francois Le Loarer, Javier Martin-Broto, Andrew Pecora, Antonio Perez-Martinez, Yuen Bun Tam, Franck Tirode, Annalisa Trama, Sandro Pasquali, Mariagrazia Vescia, Lukas Wortmann, Michael Wortmann, Akihiko Yoshida, Kim Webb, Paul H. Huang, Charles Keller, Cristina R. Antonescu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1079–1092.
https://doi.org/10.1158/1078-0432.CCR-23-2174
Published: 15 March 2024
View article titled, Translational Aspects of Epithelioid Sarcoma: Current Consensus
Open the PDF for Translational Aspects of Epithelioid Sarcoma: Current Consensus in another window
Journal Articles

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Timothy A. Yap, Matthew G. Krebs, Sophie Postel-Vinay, Anthony El-Khouiery, Jean-Charles Soria, Juanita Lopez, Alienor Berges, S.Y. Amy Cheung, Itziar Irurzun-Arana, Andrew Goldwin, Brunella Felicetti, Gemma N. Jones, Alan Lau, Paul Frewer, Andrew J. Pierce, Glen Clack, Christine Stephens, Simon A. Smith, Emma Dean, Simon J. Hollingsworth
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5213–5224.
https://doi.org/10.1158/1078-0432.CCR-21-1032
Published: 01 October 2021
View article titled, Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Open the PDF for Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Marie-Léa Gauci, Emilie Lanoy, Stéphane Champiat, Caroline Caramella, Samy Ammari, Sandrine Aspeslagh, Andrea Varga, Capucine Baldini, Rastilav Bahleda, Anas Gazzah, Jean-Marie Michot, Sophie Postel-Vinay, Eric Angevin, Vincent Ribrag, Antoine Hollebecque, Jean-Charles Soria, Caroline Robert, Christophe Massard, Aurélien Marabelle
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (3): 946–956.
https://doi.org/10.1158/1078-0432.CCR-18-0793
Published: 01 February 2019
View article titled, Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Open the PDF for Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation in another window
Includes: Supplementary data
Journal Articles

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Jeffrey R. Infante, Antoine Hollebecque, Sophie Postel-Vinay, Todd M. Bauer, Elizabeth M. Blackwood, Marie Evangelista, Sami Mahrus, Franklin V. Peale, Xuyang Lu, Srikumar Sahasranaman, Rui Zhu, Yuan Chen, Xiao Ding, Elaine R. Murray, Jennifer L. Schutzman, Jennifer O. Lauchle, Jean-Charles Soria, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2423–2432.
https://doi.org/10.1158/1078-0432.CCR-16-1782
Published: 14 May 2017
View article titled, Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
Open the PDF for Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Stéphane Champiat, Laurent Dercle, Samy Ammari, Christophe Massard, Antoine Hollebecque, Sophie Postel-Vinay, Nathalie Chaput, Alexander Eggermont, Aurélien Marabelle, Jean-Charles Soria, Charles Ferté
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (8): 1920–1928.
https://doi.org/10.1158/1078-0432.CCR-16-1741
Published: 13 April 2017
View article titled, Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Open the PDF for Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 in another window
Includes: Supplementary data
Journal Articles

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

Roman M. Chabanon, Marion Pedrero, Céline Lefebvre, Aurélien Marabelle, Jean-Charles Soria, Sophie Postel-Vinay
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (17): 4309–4321.
https://doi.org/10.1158/1078-0432.CCR-16-0903
Published: 31 August 2016
View article titled, Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
Open the PDF for Mutational Landscape and Sensitivity to Immune Checkpoint Blockers in another window
Journal Articles

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial

Cécile Jovelet, Ecaterina Ileana, Marie-Cécile Le Deley, Nelly Motté, Silvia Rosellini, Alfredo Romero, Celine Lefebvre, Marion Pedrero, Noémie Pata-Merci, Nathalie Droin, Marc Deloger, Christophe Massard, Antoine Hollebecque, Charles Ferté, Amélie Boichard, Sophie Postel-Vinay, Maud Ngo-Camus, Thierry De Baere, Philippe Vielh, Jean-Yves Scoazec, Gilles Vassal, Alexander Eggermont, Fabrice André, Jean-Charles Soria, Ludovic Lacroix
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2960–2968.
https://doi.org/10.1158/1078-0432.CCR-15-2470
Published: 14 June 2016
View article titled, Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
Open the PDF for Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial in another window
Includes: Supplementary data
Journal Articles

Targeting FGFR Signaling in Cancer

Mehdi Touat, Ecaterina Ileana, Sophie Postel-Vinay, Fabrice André, Jean-Charles Soria
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2684–2694.
https://doi.org/10.1158/1078-0432.CCR-14-2329
Published: 14 June 2015
View article titled, Targeting FGFR Signaling in Cancer
Open the PDF for Targeting FGFR Signaling in Cancer in another window